Article Text

other Versions

PDF
The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review
  1. Mia Schmidt-Hansen1,
  2. Mark Taubert2,
  3. Nathan Bromham1,
  4. Jennifer S Hilgart3 and
  5. Stephanie Arnold1
  1. 1National Collaborating Centre for Cancer, Cardiff, Wales, UK
  2. 2Velindre Cancer Centre, Velindre NHS Trust, Cardiff, Wales, UK
  3. 3Welsh Institute for Health and Social Care, University of South Wales, Pontypridd, Wales, UK
  1. Correspondence to Dr Mia Schmidt-Hansen, National Collaborating Centre for Cancer, Park House, Greyfriars Road, Cardiff CF10 3AF, Wales, UK; Mia.Schmidt-Hansen{at}wales.nhs.uk

Abstract

Objectives To assess the effectiveness and tolerability of buprenorphine for cancer pain in adults and children.

Methods We searched CENTRAL, MEDLINE, EMBASE, ISI Web of Science, ISI BIOSIS, ClinicalTrials.gov, metaRegister of Controlled Trials, WHO International Clinical Trials Registry Platform and the Proceedings of the Congress of the European Federation of International Association for the Study of Pain to early 2015.

Results We included 19 randomised controlled trials comparing buprenorphine with placebo, buprenorphine or another active drug for cancer pain. The trials included 1421 patients and examined 16 different intervention comparisons. Of the 11 studies that compared buprenorphine to another drug, 5, 3 and 3 studies, respectively, found that buprenorphine was superior, no different or inferior to the alternative treatment in side effects profile or patient preference/acceptability. Pain intensity ratings did not differ significantly between intramuscular buprenorphine and buprenorphine suppository, although intramuscular treatment was associated with more adverse events (1 study). One study found faster onset of pain relief after sublingual than subdermal buprenorphine, with similar analgesia duration and adverse event rates. 2 studies found transdermal buprenorphine superior to placebo, whereas a third study found no difference between placebo and different doses of transdermal buprenorphine. No clear dose–response relationship was found for transdermal buprenorphine. The quality of this evidence base was limited by under-reporting, small sample sizes and attrition.

Conclusions Buprenorphine might be considered as a fourth-line option compared with the more standard therapies of morphine, oxycodone and fentanyl, and even then it would only be suitable for some patients.

  • Cancer
  • Pain
  • Received 21 May 2015.
  • Revision received 9 September 2015.
  • Accepted 12 November 2015.

Statistics from Altmetric.com

  • Received 21 May 2015.
  • Revision received 9 September 2015.
  • Accepted 12 November 2015.
View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.